Protalix BioTherapeutics (PLX) EBIT Growth (3y) (2013 - 2026)
Protalix BioTherapeutics (PLX) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 69.02% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 24.14% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 44.54% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 44.34% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 81.27% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -18.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -28.30% |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn | -38.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -38.84% |
| Mar 31, 2026 | 119.66% |
| Dec 31, 2025 | -23.13% |
| Sep 30, 2025 | 38.94% |
| Jun 30, 2025 | 30.30% |
| Mar 31, 2025 | -30.39% |
| Dec 31, 2024 | 48.33% |
| Sep 30, 2024 | 60.28% |
| Jun 30, 2024 | 35.79% |
| Mar 31, 2024 | -9.44% |
| Dec 31, 2023 | -58.45% |
| Sep 30, 2023 | 9.92% |
| Jun 30, 2023 | 123.18% |
| Mar 31, 2023 | -36.15% |
| Dec 31, 2022 | -46.34% |
| Sep 30, 2022 | -26.49% |
| Jun 30, 2022 | 1.83% |
| Mar 31, 2022 | 30.35% |
| Dec 31, 2021 | -15.83% |
| Sep 30, 2021 | 20.43% |